Does the open-label study design raise any concerns regarding accurate reporting of AEs, perhaps overestimating differences in tolerability between co...
Will you start using ascinimib for all? Or are there certain patient or disease factors where you would still select TKI therapy?
Does asciminib result in harder to treat mutations if they develop?
qPCR for BCR/ABL was negative. FISH remained positive.
Is there a specific tyrosine kinase inhibitor that you would prefer to use?
The patient has also acquired mutations in BCR-ABL, namely p.Met244Val, (c.730A>G); 3.7%, which may confer resistance, and p.Phe359Cys, (c.1076T>...
There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?
The said patient has been on Imatinib for 2.5 years and is In MMR. Last rt-PCR was 0.04.
For instance, do you ever start with dasatinib 50 mg daily? Are there any titration schedules that you follow?
if so, are there specific cytogenetic, molecular, clinical, or hematologic factors that you take into consideration?
Thrombosis was ruled out and no etiology was found. Would you start ponatinib back at a lower dose, transition to omacetaxine or begin transplan...
Drug information indicates a patient may need 3-4 months off TKI. This seems like a long time off drug. Would a MMR of a certain duration make it less...